sorafenib has been researched along with Exanthem in 16 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (18.75) | 29.6817 |
2010's | 10 (62.50) | 24.3611 |
2020's | 3 (18.75) | 2.80 |
Authors | Studies |
---|---|
Abbas, MN; Kichenadasse, G; Tan, WS | 1 |
Ghosn, M; Ghosn, S; Halabi-Tawil, M; Kaikati, J; Matar, S | 1 |
Fuji, S | 1 |
Chiba, T; Fukudo, M; Hatano, E; Ito, T; Kamba, T; Matsubara, K; Mizuno, T; Ogawa, O; Seno, H; Shinsako, K; Uemoto, S; Yamasaki, T | 1 |
Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O | 1 |
Amitay-Laish, I; Didkovsky, E; Hendler, D; Hodak, E; Lotem, M; Merims, S; Ollech, A; Popovtzer, A; Stemmer, SM | 1 |
Gao, C; Huang, Z; Jia, W; Jiang, X; Lau, WY; Li, J; Li, X; Luo, X; Shen, F; Si, A; Xing, B; Yang, T | 1 |
Archer, SL; Barst, RJ; Bond, L; Coslet, S; Gomberg-Maitland, M; Lacouture, ME; Maitland, ML; Perrino, TJ; Ratain, MJ; Sugeng, L | 1 |
Addeo, R; Caraglia, M; Colucci, G; Del Prete, S; Frezza, AM; Giuliani, F; Montella, L; Rizzo, S; Russo, A; Santini, D; Tonini, G; Venditti, O; Vincenzi, B | 1 |
Barete, S; Billemont, B; Blanchet, B; Cabanes, L; Coriat, R; Francès, C; Garrigue, H; Goldwasser, F; Knebelmann, B | 1 |
Bracarda, S; Cortesi, E; D'Angelo, A; Ferraù, F; Merlano, M; Monti, M; Ruggeri, EM; Santoro, A | 1 |
Abrahamova, J; Bortlicek, Z; Buchler, T; Dusek, L; Melichar, B; Pavlik, T; Poprach, A; Puzanov, I; Vyzula, R | 1 |
Fujishima, N; Habuchi, T; Hasunuma, N; Hatakeyama, S; Horikawa, Y; Inoue, T; Narita, S; Notoya, T; Numakura, K; Ohyama, C; Satoh, S; Tsuchiya, N | 1 |
Hilger, RA; Kredtke, S; Scheulen, ME; Seeber, S; Strumberg, D | 1 |
Awada, A; Brueckner, A; Christensen, O; Clark, JW; Hirte, H; Hofstra, E; Piccart, P; Schwartz, B; Seeber, S; Strumberg, D; Voliotis, D | 1 |
Bonomi, L; Imarisio, I; Paglino, C; Porta, C | 1 |
4 review(s) available for sorafenib and Exanthem
Article | Year |
---|---|
Toxicity of sorafenib: clinical and molecular aspects.
Topics: Animals; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Exanthema; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2010 |
Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Disease Management; Exanthema; Humans; Keratoacanthoma; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pruritus; Pyridines; Severity of Illness Index; Skin; Sorafenib | 2012 |
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Eruptions; Exanthema; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2006 |
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
Topics: Acneiform Eruptions; Antineoplastic Agents; Benzenesulfonates; Erythema; Esophagitis; Exanthema; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
5 trial(s) available for sorafenib and Exanthem
Article | Year |
---|---|
Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease Progression; Exanthema; Fatigue; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Serum Albumin; Serum Albumin, Human; Sorafenib; Treatment Outcome | 2015 |
Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Diarrhea; Drug Administration Schedule; Exanthema; Fatigue; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Pilot Projects; Prospective Studies; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2017 |
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
Topics: Adult; Aged; Benzenesulfonates; Diarrhea; Drug Discovery; Drug Dosage Calculations; Exanthema; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Exanthema; Female; Glucuronosyltransferase; HLA-A24 Antigen; Humans; Kidney Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2013 |
Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006.
Topics: Adult; Area Under Curve; Benzenesulfonates; Diarrhea; Drug Administration Schedule; Exanthema; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2004 |
7 other study(ies) available for sorafenib and Exanthem
Article | Year |
---|---|
Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Exanthema; Humans; Keratoacanthoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Skin Diseases; Sorafenib | 2021 |
Disfiguring sorafenib associated eruptive squamous cell carcinomas in a patient with acute myeloid leukemia.
Topics: Carcinoma, Squamous Cell; Exanthema; Humans; Keratoacanthoma; Leukemia, Myeloid, Acute; Skin Neoplasms; Sorafenib | 2023 |
How Can We Distinguish Sorafenib-Associated Skin Rash From Skin Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem-Cell Transplantation?
Topics: Exanthema; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Sorafenib; Transplantation, Homologous | 2021 |
Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Exanthema; Female; Hand-Foot Syndrome; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult | 2014 |
Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic.
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Exanthema; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Steroids; Sulfonamides; Vemurafenib | 2016 |
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Eruptions; Exanthema; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis | 2010 |
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Exanthema; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Registries; Retrospective Studies; Skin; Sorafenib; Sunitinib; Treatment Outcome | 2012 |